Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

The American Journal of Cardiology
R L Ellen, R McPherson

Abstract

To assess the long-term efficacy and use of fenofibrate together with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin") in the treatment of elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol, we conducted a study that compared a before- and after-case series. The study involved 80 patients with a diagnosis of combined hyperlipidemia and existing coronary artery disease (81% of patients) or outpatients with > or = 3 risk factors for coronary artery disease who had been receiving treatment at a tertiary care center. Fasting biochemical measures were obtained at baseline during monotherapy with a statin consisting of pravastatin 20 mg once daily or simvastatin 10 mg once daily (39 patients) or fenofibrate 300 mg once daily (41 patients), and during a 2-year period of combination therapy. This combination therapy comprised fenofibrate 300 mg once daily or micronized fenofibrate 200 mg once daily taken together with pravastatin 20 mg once daily (63 patients) or simvastatin 10 mg once daily (17 patients). The main outcome measures were: (1) absolute and percent change in total cholesterol, triglycerides, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol; (2) per...Continue Reading

References

Nov 1, 1991·The American Journal of Cardiology·S J BoccuzziM E Keegan
Feb 15, 1991·Annals of Internal Medicine·J P Deslypere, A Vermeulen
Jul 1, 1991·Neurology·S F LondonS P Ringel
Feb 1, 1990·Annals of Internal Medicine·G E Marais, K K Larson
Apr 1, 1990·Postgraduate Medical Journal·A D Kogan, S Orenstein
Mar 1, 1989·Arthritis and Rheumatism·J A GoldmanR J Johnson
Jul 1, 1988·Annals of Internal Medicine·C EastS M Grundy
Oct 1, 1988·Annals of Internal Medicine·P Reaven, J L Witztum
Oct 15, 1988·Annals of Internal Medicine·J Z AyanianR M Stone
Feb 1, 1980·European Journal of Clinical Investigation·A ChaitJ D Brunzell
Jan 1, 1993·The American Journal of Medicine·O WiklundS O Olofsson

❮ Previous
Next ❯

Citations

Jul 29, 2009·PPAR Research·Tiangang Li, John Y L Chiang
Oct 23, 2002·Journal of General Internal Medicine·Michael L Green
May 24, 2003·Current Diabetes Reports·Michael H Davidson
Aug 29, 2007·International Journal of Nanomedicine·Konstantinos Tziomalos, Vasilios G Athyros
Jul 17, 2008·Vascular Health and Risk Management·Navin K KapurRoger S Blumenthal
Feb 3, 2005·Current Atherosclerosis Reports·Benjamin J Ansell
Dec 21, 2000·Current Atherosclerosis Reports·M Miller
Aug 7, 2001·Current Atherosclerosis Reports·T A Jacobson
Nov 30, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·N BroedersD Abramowicz
Jun 20, 2001·Diabetes, Obesity & Metabolism·J R Burnett, G F Watts
May 19, 2007·Journal of the American Pharmacists Association : JAPhA·Patrick O Curtin, William N Jones
May 11, 2010·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Juan F Ascaso
Feb 24, 2007·Archives of Gerontology and Geriatrics·A BellomoV Marigliano
Jul 20, 2005·Journal of Clinical Pharmacology·Linda E GustavsonH Daniel Yannicelli
Mar 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B KasiskeUNKNOWN National Kidney Foundation
May 14, 2003·Pharmacotherapy·Chad R Worz, Michael Bottorff
Jan 13, 2006·The Journal of Clinical Hypertension·Terry A Jacobson, Franklin H Zimmerman
Mar 10, 2004·The American Journal of Medicine·Robert S Rosenson
Jun 5, 1999·The American Journal of Cardiology·D J Rader, S M Haffner
Dec 7, 2002·The American Journal of Cardiology·Michael H Davidson
May 28, 2004·Biochemical Pharmacology·Toshio KubotaRyozo Oishi
Apr 4, 2006·The American Journal of Cardiology·Harold Bays
Sep 1, 1999·Rheumatic Diseases Clinics of North America·C A Friedrich, D J Rader
Oct 24, 1998·Endocrinology and Metabolism Clinics of North America·S M Grundy
Mar 18, 2004·Primary Care·Michael L Green
Sep 14, 1999·The American Journal of Medicine·C East
Aug 17, 2004·American Heart Journal·Philippe O Szapary, Daniel J Rader
Aug 3, 2006·The British Journal of Dermatology·C AssafS Whittaker
Jul 4, 2002·Current Medical Research and Opinion·George LiamisMoses Elisaf
Jun 20, 2003·Current Medical Research and Opinion·A S WierzbickiC B Byrne
Jul 9, 2011·Expert Opinion on Pharmacotherapy·Theodosios D Filippatos, Moses S Elisaf
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Evan A Stein
Jul 16, 2008·Orvosi hetilap·György ParaghMárk László

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.